HEALTH BIOTECH LTD

(WHO-GMP ISO 9001:2008 Certified Company)

Company Overview
2017
Transaction Overview
Transaction Overview
Company Health Biotech Limited (HBL) is basically a research and development based
pharmaceutical company, producing quality, affordable generic and innovative
medicines. Health Biotech Ltd. (HBL) is a Chandigarh based technology
The corporatedriven pharmaceutical
office is situated atcompany established
Chandigarh in 2005
'The City Beautiful'.

Manufacturing of finished formulations with specialisation in generic

Business Manufacturing & Marketing of finished formulations with specialization in generic
injectables including: injectables including:
Lyophilized injectables Lyophilized injectables
Dry/liquid injectables Dry/liquid injectables
Liposomal Injectable
Pre-filled syringes
Pre-filled syringes
Liquid ampoules/vials Liquid ampoules/vials
Other products include: Other products include:
Eye/ear/nasal drops Eye/ear/nasal drops
Sterile/non sterile ointments Tablets & capsules
Liquid/Dry Syrup Sterile/non sterile ointments

Facilities State of the art manufacturing facility is located at foot hills of Himalayas at Baddi.
The facility is WHO-GMP, ISO 9001-2008 certified and adheres to MHRA norms.
Latest Automatic Tunnel System, Lyophilization capacity and Automatic Fill-Form
and Seal technology for manufacturing sterile injectables and pre-filled syringes
further adds technology advancements in the facility.
Recently developed dedicated Oncology drugs manufacturing unit adhering to EU
GMP norms
EVOLUTION

Commercial Production started In 2005.

One of the early birds to set up Pharmaceutical Manufacturing in the Excise Free Zone .
Went on to become one of the leading contract manufacturers.
Started contract manufacturing for the leading Indian Companies like Cipla, Cadila, Piramal,
Vetoquinol, Lupin, etc .
Manufacturing capacities expanded manifold to cater to ever growing demand .
Today having a huge manufacturing area spread over more than 100,000 Sq.Ft
Shifted to its own domestic & international Marketing in 2009.
Established Govt. Of India approved R & D Centre engaged in Plant Research, Nano Particle,
Liposomal technology and Isolation Of Heparin from Bio Waste.
Key Projects of HBRC include Isolation Of Heparin from Bio Waste and Development
of recombinant DARBEPOETIN ALFA.
Company
Overview
Strong management team with over 20 Presence in over 25 countries across the
years of experience and a vision to globe with products registered in Latin
become one of the largest technology America and South East Asia in the less
and research based injectables regulated and semi regulated markets
manufacturer in Asia
Plans to enter regulated markets of Europe
Experienced and well-trained middle after acquiring EU GMP certification for new
management team facility
Competent Global
Management Presence Modern manufacturing facility
Specialized products with low Team
with WHO GMP certification
price erosion and increasing
adhering to UK MHRA norms
demand catering to niche Specialized
market segment Products and Manufacturing
Niche Market Capabilities Facility is equipped with latest
automatic tunnel system,
Less competitive market space
lyophilisation equipments to make
with few integrated players and Established sterile injectables and pre-filled
high entry barriers Sales and In-House R&D syringes
Distribution capabilities
Network

Efficient sales team of skilled Team of qualified scientists and

associates and strong distribution professionals engaged in R&D activities
channel with several C&F agents and
stockists across India Research area includes New Drug
Delivery Systems (NDDS) focused on
Strategic tie-ups with international nano particle and liposomal carriers,
players for overseas marketing and new molecules, etc.
distribution
Brief Promoter Profile
Mr. Parmjit Arora
(Managing Director)

Over 22 years of marketing, distribution and manufacturing experience in Pharmaceutical formulations

Carried out distribution for 10 years for Ranbaxy Generics and Consumer Healthcare products in the
state of Punjab, Himachal Pradesh, J&K, Haryana and Chandigarh

Mr. Gaurav Chawla

(Director)
Over 14 years of experience in pharmaceutical industry
Associated with HBL since its inception and played an instrumental role in its growth
Currently manages the purchasing and packaging functions of HBL
Key Strength
Key Strength
Product Portfolio
 Current
Product Portfolio Product Portfolio
Key product segments include:

Oncology Injectables

Hormones & Steroids

Cardiovascular

Higher Antibiotics & Critical Care

PPI (Proton Pump Inhibitor )
Beta Lactams and Non Beta Lactams
Nutraceuticals food supplements
Hormones
Pre-Filled Syringes
Core competency in manufacturing of quality injectables including lyophilized
injections

Diverse product portfolio encompassing diverse therapy areas including oncology,

cardiovascular, antibiotics, etc.

Strong capabilities in a range of delivery systems such as injections, syrups, drops,

liquid/ dry syrups , Ointments and lotions, sachets etc.
Manufacturing
Manufacturing Facilities
FACILITY 1 (Unit I HEALTH BIOTECH LTD
1 Lac Sq ft. ( Dry & Liquid Injections, Syrups, Ointments, PFS, Eye Drops )

With key focus on niche injectables segment, HBL has made initial capital investments and developed
adequate manufacturing capacities for future growth prospects

HBL proposes to attain optimum capacity utilization by increasing sales of products with aggressive
marketing through diverse sales channels

Facilities employs advanced manufacturing processes that include:

Pre-Filled Syringe System
Automatic Tunnel Systems for Dry and Liquid Injections
Fill, Form and Seal of Eye/Ear Drops
Pouch Packing System for Dry and Liquid Syrups

Facility also include one independently operating analytical laboratory, in-house warehousing
(30,000 sq.ft. in Baddi) and support for packaging & logistics for domestic and export sales

FACILITY 1 (Unit II) EU- GMP Compliant Lyophilizing Unit

12,000 Sq Ft (Lyophilized Injections)

Equipped with lyophilization technology adhering to EU GMP standards for manufacturing of pre
filled syringes
Manufacturing Lines
Manufacturing Capacities

Manufacturing Capacities

S. No. Section Units

1 Eye Ear Drop 15120000

2 Liquid Injection 133200000

3 Dry Powder Injection 66240000

4 PFS 8640000

5 Syrup 33120000

6 Dry Syrup 16560000

7 Ointment 9720000
Research & Development
RnD Capabilities R&D Capabilities

HBL has significant R&D capabilities with qualified team of scientists and professionals and a
fully equipped HBL Research Center recognized by Govt. of India

Research area include Novel Drug Delivery System, Fixed Dosage Combinations (FDC) &
natural products research

Focused on development of various drug delivery & drug targeting systems to improve efficacy and safety profile of

drugs

Key achievements of the R&D team include: S.No. Projects in Pipeline

Development of lyophilized injectable paracetamol

Biosimilar recombinant Erythropoietin and Darbepoetin
Lyophilized CNTQ resuscitative injection
Sustained release formulation of sildenafil
Heparin cream with enhanced transdermal permeation
Amikacin nano-formulation
Cefoperazone intramammary injectables suspension (Brand Name:Mastiwok): Technology sold to
Wockhardt
Regulatory Approvals
India

Certificate of Good Manufacturing Practice (GMP)

Certificate of WHO GMP
ISO 9001:2008 Certificate
G.L.P (Good laboratories Practice ) Certificate
Manufacturing & Marketing Certificate
Capacity Certificate
Production Certificate
Non Convection Certificate
Neutral Code Certificate
Certificate of Importer Exporter Code
International

Iraq MOH

Srilanka CDDA

NAFDAC Nigeria

MOH- DMEQC Uzbekistan

MOH Yemen

MOH Syria

.
Business Overview
Business Segment
CONTRACT RESEARCH AND MANUFACTURING SERVICES
(CRAMS)
Executive Summary

Leading pharma The countrys pharma industry accounts for about 1.4 per cent of the global pharma industry in
producer value terms and 10 per cent in volume terms

Among fastest growing The Indian pharmaceutical industry revenue is expected to expand at a CAGR of 17.8 per cent
industries during 200816 and reach USD36 billion

Rapidly growing The healthcare sector in India is expected to reach USD100 billion by 2015 from the current
healthcare sector USD65 billion

Growing generics The generics market is expected to grow to USD26.1 billion by 2016 from
market USD11.3 billion in 2011; Indias generics market has immense potential for growth

Ranked 5th in terms of Attracted 5 per cent of the total FDIs into India from April 2000 to March 2013
attracting FDI Cumulative FDI inflows worth USD10.3 billion from April 2000 to March 2013

Source: India Biz, PharmaBiz, Frost and Sullivan report on Indian Pharmaceutical Market, Aranca Research
Note: API - Active Pharmaceutical Ingredient, USFDA - United States Food and Drug Administration, CAGR - Compound
Annual Growth Rate
Major Segments of Pharmaceutical Industry

fIndia is expected to supplant Italy as the second largest producer

Active pharmaceutical of APIs globally
ingredients (APIs)
Drug companies from India filed 49 per cent of the overall Drug
Master Filings (DMF) filed in the US in 2012

Fragmented market with more than 1,000 players

Contract research and
manufacturing services CRAMS industry is estimated to have reached USD7.6 billion in
(CRAMS) 2012, up from USD3.8 billion in 2010

Pharmaceutical
Industry Largest exporter of formulations in terms of volume with 14 per
cent market share and 12th in terms of export value
Formulations Domestic market size is currently valued at USD11.2 billion
Double-digit growth expected over the next five years

Biosimilars revenues are expected to touch USD550600 million

by 2015 from USD200 million in 2008
Biosimilars The government plans to allocate USD70 million for local players
to develop biosimilars

Source: India Biz, PharmaBiz, Frost and Sullivan report on Indian Pharmaceutical Market, Aranca Research
Note: API - Active Pharmaceutical Ingredient, USFDA - United States Food and Drug Administration, CAGR - Compound
Annual Growth Rate
Health
HealthBiotech
BiotechLimited
LimitedLeading
LeadingContract
ContractManufacturer
Manufacturer
Contract Research and We undertake contract/toll manufacturing for various companies
including Indian multinationals. We ensure maintenance of high quality
Manufacturing Service
standards at the most affordable prices.
(CRAMS)
Our client list is long, some of the known names are: Alembic, Alkem,
Cipla, Lupin, Cadila, Unichem, Wockhardt (now Vetoquinol), Piramal,
Intas, Concept Pharmaceuticals, Novartis, Claris Life Sciences, and
others.

PRODUCT QUALITY The tech savvy production team of HBL qualifies for
maintenance of international standards of drug production, product
quality and assaying.

Our Modern hi-tech automatic manufacturing processes are

available for manufacturing consistently high-quality products.

COST COMPETITIVENESS We have deployed latest Automatic Tunnel Systems which is a capital
intensive, quality & cost competitive process.
Health biotech contributes to the availability of good medicinal products
by stimulating the development of innovative new medicines.

DELIVERY SCHEDULE With an intricate planning objective which involves control of incoming
materials, maintenance of an operating schedule of the production line,
determining the number of lines and shifts needed, the manpower
required and the process yield, our endeavors are towards ensuring that
seamless deliveries are affected to our partners for optimum market
planning.
Top Therapies offered by Health Biotech
Top Therapies Offered by Health Biotech
S.No. Product Strength Therapeutic Segment
1 Doxorubicin Injection 10mg/50mg Anticancer
2 Gemcitabine Injection 200mg;1gm Anticancer
3 Oxaliplatin Injection 50mg/25ml; 100mg/50ml Anticancer
4 L-Asparginase Injection 5000 IU;10000 IU Anticancer
5 Bleomycin Injection 15 Unit Anticancer
6 Carboplatin Injection 150mg;450mg;600mg Anticancer
7 Docetaxel Injection 20mg;80mg;120mg Anticancer
8 Paclitaxel Injection 30mg;100mg;260mg;300mg Anticancer
9 Heparin Injection 5000/25000 IU Anticoagulant
10 Enoxaparine Sodium PFS 20mg/40mg/60mg/80mg Anticoagulant
11 Vasopressin PFS 20 IU Cardiovascular
12
Tigecycline 50 mg Antibiotic

13 Ceftriaxone + Sulbactam 1.5 gm Antibiotic

14 Iron Sucrose Injection 50mg/2.5 ml, 100mg/5ml Iron Preparation
15 Refampicin Injection 150mg/300mg/600mg Anti Tuberculosis
16 Imipenem+Cilastatin Injection 500mg/1gm Antibiotic
17 Piperacillin + Tazobactum 4.5gm Antibiotic
18 Meropenem Injection 500mg/1gm Antibiotic
19 Ertapenam Injection 1gm Antibiotic
20 Streptokinase Injection 7.5 Lac/ 15 Lac IU Cardiovascular
Top Therapies offered by Health Biotech

21 Urokinase Injection 5 Lac/7.5 Lac IU Cardiovascular

22 Aprotinin Injection 100000 KIU/ 500000 KIU Anticogulant
23 Azethromycin Injection 500 mg Antibiotic
24 Aztreonam Injection 500mg/1gm/2gm Antibiotic
25 Clarithromycin injection 500 mg Antibiotic
26 Tramadol Injection 50mg Analgesic
27 Indomethacin Injection 1mg NSAID
28 Pantoprazole Injection 40mg PPI
29 Omeprazole Injcetion 20mg;40mg PPI
30 Esomeprazole Injection 40mg PPI
31 Cefotaxime Injection 250mg;500mg;1gm Antibiotic
32 Cefipime Injection 500mg; 1gm Antibiotic
33 Amoxycillin + Clavulanate Potassium 300mg;600mg;1.2gm Antibiotic
34 Ceftriaxone + Tazobactum Injection 1.125gm Antibiotic
35 Cefepime + Sulbactum Injection 1.5gm Antibiotic
36 Testosterone Enanthanate 100mg;250mg Hormone
37 Testosterone Propionate 25mg;100mg Hormone
Human Chorionic Gonadotrophin
38 (HCG) 2000IU;5000IU;10000IU Hormone
39 Stanzolol Injection 50mg/ml Steroid
40 Somatropin 4IU/10IU/12IU/15IU/24IU Steroid
new product addition in Health Biotech List
S.No Product Strength Therapeutic Segment
1 Colistimethate Sodium Inj 1 Million Units Antibiotic

2 Ticarcillin & Clavulanic acid Inj 3gm.+100mg Antibiotic

3 Aztreonam Inj 1gm/2gm Antibiotic

4 Meropenem & Sulbactum Inj 1gm+.500mg Antibiotic

5 Cefipime & Tazobactam Inj 1gm+125mg Antibiotic

6 Caspofungin Inj 50mg /70mg Antifungal

Iron Preparation
7 Ferric carboxymaltose Inj 500mg

8 Efavirenz Syrup 30mg/ml Retroviral infection

9 Risperidone Inj 37.5mg Antipsychotic

10 Risperidone Inj 25.0mg Antipsychotic

11 Fluorouracil cream 5% Anticancer

 Nutraceuticals food supplements Products

S.No. Products
1 Garcinia cambogia Capsule
2 Fat Burner Tablet ( Green Tea extract)
3 Multivitamins for Men Capsule
4 Multivitamins for Women Capsule
5 Vitamin D3 Tablet
6 DHEA 25mg (Dehydropiandrosterone)
7 ALA (Alpha Lipoic Acid) Tablet
8 Creatine 2000mg Capsules
9 Glutamine 1000mg Capsules

10 BCAA 1000mg Capsules

11 Digestive Enzymes Tablet/Capsule
12 Zinc Citrate Tablet
DIRECT MARKETING
 DIRECT MARKETING

Direct Marketing is the latest trend in the world and is

catching up fast in India as well.

Health Biotech is the first company to market products in a

systematic way throughout the country.

We have planned to appoint business managers who can

look after all the states to service, training and help our
business associates in improving their business and profits.
 INSTITUTIONAL BUSINESS

HBL focus to work on 105 Govt /Semi Govt institutes tender.

HBL received drug approvals from 20 Govt. and Semi Govt. institutions in India
for supply of drugs manufactured by the company under its own brand
Detail of the Institutional Business (RC) available with the Company

S.No Name of the Institution State

1
AIIMS Delhi

2 APMSIDC Hyderabad
BHILAI STEEL PLANT
3 Raipur

4 Controller of Store Punjab Chandigarh

5 Director Health Services Agartala

Arunachal
6 Director Health Services Pradesh

7 Rajastan Medical Services Corporation Limited Jaipur

8 Govt Multi Speciality Hospital Sector-16 Chandigarh

9 Govt. Medical College Hospital Sector-32 Chandigarh

10 Haryana Medical Services Coporation Panchkula

Detail of the Institutional Business (RC) available with the Company

S.No Name of the Institution State

11
Jammu Kashmir Medical Services Corporation Jammu

12 National Rural Health Mission Guwahati

13 North Delhi Municipal Corporation Delhi

14 PGI Chandigarh

15 Punjab Health System Corporation Mohali

16 South Delhi Municipal Corporation Delhi

17 Steel Authority of India Bokaro

18 King George Medical University Lucknow

National Institute of Mental Health and Neuro Sciences
19 Banglore

20 Safdarjang Hospital, New Delhi

INTERNATIONAL BUSINESS
WORLD MARKETS
Estimated to be a US$1200 billion market in 2017 (including estimated unaudited pharmaceutical sales)
Market expected to grow at a rate of 5% to 7%
Regulated markets (US, Europe and Japan) account for almost 65 % of the market in terms of revenue,
growing at the average rate of 4 5%.
North America (including Canada) is the single largest market accounting for approx. 37 % of global sales and
is growing at the rate of 3 5 %
EU is the second largest world market, comprising about 17% of global sales and growing at a rate of 1 3 %

Source: IMS Health, September 2015

EMERGING TRENDS

Growing importance of generics in world markets

Pressure from healthcare providers and insurance companies to reduce healthcare costs driving usage of generic
drugs
Increasing patent expirations driving generic drug availability.

Increasing focus is being driven towards life style and critical ailments
CVD, Oncology, Central Nervous System and Respiratory disorders are the fastest growing healthcare segments.
Oncology market maintains its status as an outperformer in the global market.
By 2015, worldwide sales of Oncology products totaled USD 100 Billion ( according to IMS Health MIDAS, 2015)
with Pharmerging markets accounting to 8% of the sales.
By 2015, the global oncology market was growing by 6.8 % driven by 15.2% growth in Pharmerging markets.
The global oncology market, driven by targeted therapeutics, earlier detection, longer treatment duration, and
extended indications, will grow to approximately USD 85 billion by 2016.

Source: IMS Health MIDAS, 2015

The generic drugs market which is expected to grow at 10%-12% over the next few years is a key growth
area for emerging pharmaceutical manufacturers
International Business

We are currently exporting our products to semi and non

regulated ROW markets covering Latin America, CIS,
South East Asia and Africa.

We have already established our presence in nearly 25

countries with 19 of our products already registered in 9
countries.
Geographical Presence
Currently Present

Plan to enter
CIS CIS
Ukraine Tajikistan
Europe Uzbekistan
Moldova
Russia
kazakhstan
ASEAN
Vietnam
Middle East Cambodia
Iraq Myanmar
Iran Malaysia
Latin America Philippines
Guatemala
Syria South Asia
Lao
Peru India
Venezuela Sri lanka
Cuba
Africa
costa rica Nigeria Nepal
El Salvador Morocco
Ecuador Mozambique
Angola
Geographical Presence

Focus to expand in other countries in above geographies such as Indonesia, Philippines, Sri Lanka and
Venezuela, and already has products under registration in these countries. Also plans to expand to
Europe, Middle East, SEA ,CIS and African countries.

Filed dossiers for about 47 drug formulations in Asia, CIS, Africa & Latam and expects to launch these
drugs in next 6-12 months

Has also developed formulations and compiled dossiers for three major Oncological generics
(Docetaxel, Gemcitabine and Oxaliplatin) for entering European markets post EU GMP market
authorization grant.
International Regulatory Approval

Iraq MOH

Srilanka CDDA

NAFDAC Nigeria

MOH- DMEQC Uzbekistan

MOH Yemen

MOH Syria

.
HBL Registered Product

S.N Product Country

1 Clindamycin Injection 300mg/2ml
Srilanka
2 Streptokinase Injection 1500000 IU
Srilanka
3 Citicoline 1000mg/4ml injection Uzbekistan
4 Citicoline 500mg/2ml injection Uzbekistan
5 Vasopressin Injection 20 units/ml Malaysia
6 Meropenem 500mg powder for Inj Guatemala
7 Cefepima 1gm Inj Guatemala
8 Vancomicina Clorhidrato 500 mg powder for Inj Guatemala
9 Iron Sucrose 100mg/5ml Inj Peru
10 Vassopressin 20 iu/ml Inj Peru
11 Medroxyprogestrone Inj Cuba
12 Iron Sucrose 100mg/5ml Inj Venenzuela
13 Imipenem 250 mg + Cilastatin 250 mg Nigeria
14 Docetaxel 120mg Inj Nigeria
HBL Registered Product

S.N Product Country

15 Risperidone 25mg Inj
Ecuador
16 Risperidone 37.5mg Inj Ecuador

17 Fluorouracil Cream 5% - 30gms Ecuador

18 Aminophylline 25mg/ml Inj Ecuador

19 Ondansetron 2mg/ml 2ml Ecuador

 SNAPSHOT- PRODUCT DEVELOPMENT

SEA/ASIA CIS/RUSSIA LATAM AFRICA TOTAL

Registration Till Date 3 2 12 2 19

Filling Till Date 34 5 2 6 47

Target filings in FY 18 5 14 18 55
16-17
Target launches in FY 6 6 6 18
16-17
Products under 20-25 8-12 10 10 50-57
development
DOSSIER FILINGS TILL DATE AND EXPECTED LAUNCHES

We have already filed 47 dossiers in 10 countries in SEA/Asia ,CIS, Africa and

LATAM region.

Sri anka 2
Vietnam - 16
Myanmar 11
Philippines-- 2
Jordan--3
Uzbekistan 5
Morocco-4
Nigeria- 2
Dominican Republic 1
Guyana -1
HBL Filled Dossiers List
Sn Product Country
1 Somatropin 24 IU Srilanka
2 Cloxacillin for Injection 500 mg Srilanka
3 Meropenem 1 gm Vietnam
4 Imipenem 500mg + Cilastatin 500 mg Vietnam
5 Cefroperazone & Sulbactam 2 gm Vietnam
6 Piperacillin & Tazobactum 4.5 gm Vietnam
7 Esomeprazole 40 mg with solvent Vietnam
8 Omeprazole 40 mg with solvent Vietnam
9 Rabeprazole 20 mg with solvent Vietnam
10 Pantoprazole 40 mg with solvent Vietnam
11 Omeprazole 40 mg with solvent Myanmar
12 Ceftriaxone 1gm for Injection Myanmar
13 Meropenem 1gm for Injection Myanmar
14 Piperacillin 4gm +Tazobactum 0.5gm for Injection Myanmar
15 Imipenem 500 + Cilastatin 500mg for Injection Myanmar
16 Ceftazidime 1gm for Injection Myanmar
17 Cefoperazone 1000 mg + Salbactum 500 mg for Inj Myanmar
18 Paclitaxel 100mg/16.7 ml Injection Myanmar
Epirubicin 50mg/25 ml Injection (lyop)
19 Myanmar
Carbplatin 10mg/ml 15 ml Injection
20 Myanmar
Docetaxel 120mg/3ml Injection
21 Myanmar
22 Ciprofloxacin Opthalmic Solution USP Vietnam
23 Ompeprazole for Inj (Lyophilized) Vietnam
24 Esomeprazole for Inj (Lyophilized) Vietnam
HBL Filled Dossiers List
Sn Product Country

25 Moxifloxacin Hydrochloride Eye drops Vietnam

26 Tobramycin Opthalmic solution USP Vietnam
27 Ofloxacin Opthalmic solution USP Vietnam
28 Esomeprazole for Inj (Lyophilized) Vietnam
29 Rabeprazole sodium for Inj (Lyophilized) Vietnam
30 Vasopresin 20U PFS Philippines
31 Colistimethate Sodium 1 Million Units Philippines
32 Tobraycin 3% Jordan
33 Dorzolamide 2% Jordan
34 Timolol melate 0.5% Jordan
35 Cyclophosphamide 200 mg inj Uzbekistan
36 Cyclophosphamide 1 gm inj Uzbekistan
37 Vincristine Sulphate 1 gm Uzbekistan
38 Enoxaparin PFS 40mg/0.4ml Uzbekistan
39 Iron Sucrose Inj 100mg/5ml Uzbekistan
40 Dactinomycin for Injection USP Morocco
41 Paclitaxel injection 30 mg Morocco
42 VINORELBINE INJECTION 20mg/5ml Morocco
43 CARBOPLATINE ISIO 450mg/45ml Morocco

44 Human Chorionic Gonadotrophin for Injection BP 5000 IU Nigeria

45 ALPHA BETA ARTEETHER INJECTIONS 150mg Nigeria

46 Hydrocortisone Sodium Succinate 100 mg USP Dominican Republic

47 Meropenam 500 mg Inj Guyana

BUSINESS MODELS
SERVICES OFFERED BY OUR CHANNEL PARTNERS

Regulatory

Importation & Warehousing

Sales and Marketing

Product Launch & Exhibition

Market Survey

Information System
Key Strength of HBL

Low cost generic manufacturing

Experience of Developing and Marketing Anticancer drugs

New Facility in place for Anticancer Formulation

Future Growth Strategy

To establish itself as a reputed brand by extensive marketing of

HBL product range across India
Establish HBL
Branded Manufacturing expertise acquired as contract manufacturer can be
formulations leveraged to manufacture quality products under HBL brand

Establish strong sales and distribution network for each business

Establish Sales & division to achieve significant penetration in Tier II and III cities in
Distribution India
Network
Appoint local distributors and field force for higher penetration
Future Growth Strategy

Increase number of registered products in these markets by filing

dossiers
Expansion in Explore the institutional and tender market in these countries and
Emerging and actively participate in such contracts
Semi-Regulated Increase penetration in these markets through appointment of local
Markets distributers and significant marketing initiatives

Rapid commissioning of the upcoming EUGMP compliant facility to

enter regulated markets
Entry to Regulated After getting certified, HBL plans to enter European and other regulated
Markets markets with its range of injectable products which has tremendous
potential . Top 5 targeted European markets are Spain, France,
UK , Italy and Portugal
Organize plant audits from 10 countries in Africa and LATAM region.

Appointing our own Country Managers to carry out Brand Promotion

activities (Launch events for company, CME, participating in local events and
International Brand
Marketing exhibitions for HBL).
Setting up our own Branch Offices in overseas markets ( Philippines,
Colombia)
Sustainable Growth Strategy

Continued growth of Strengthen Presence in

Generics Business Lifestyle Drugs

Sustainable Penetrate Regulated

Brand Marketing
Growth Markets

Broad Basing the Product NDDS and Innovative

Basket Products